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Abstract
Background: Small chemical compounds which target chemokine receptors have been developed against human
immunodeficiency virus type 1 (HIV-1) and are under investigation for use as anti-HIV-1 microbicides. In addition,
monoclonal antibodies (mAbs) against chemokine receptors have also been shown to have anti-HIV-1 activities.
The objective of the present study was to screen a panel of three anti-CXCR4 specific monoclonal antibodies
(mAbs) for their ability to block the HIV-1 infection using in vitro activated primary peripheral blood mononuclear
cells (PBMCs).
Results: PBMCs from normal donors were pre-activated with anti-CD3 and anti-CD28 mAbs for 1 day, and aliquots
were infected with a low dose of CCR5-tropic (R5), CXCR4 tropic (X4) or dual tropic (X4R5) HIV-1 isolates and
cultured in the presence of a panel of anti-CXCR4 mAbs. The panel included clones A145 mAb against the N-
terminus, A120 mAb against a conformational epitope consisting of extracellular loops (ECL)1 and ECL2, and A80
mAb against ECL3 of CXCR4. Among these mAbs, the A120 mAb showed the most potent inhibition of infection,
by not only X4 but surprisingly also R5 and X4R5 HIV-1. The inhibition of R5 HIV-1 was postulated to result from
the novel ability of the A120 mAb to induce the levels of the CCR5-binding b-chemokines MIP-1a, MIP-1b and/or
RANTES, and the down modulation of CCR5 expression on activated CD4
+ T cells. Neutralizing anti-MIP-1a mAb
significantly reversed the inhibitory effect of the A120 mAb on R5 HIV-1 infection.
Conclusions: The data described herein have identified a unique epitope of CXCR4 whose ligation not only
directly inhibits X4 HIV-1, but also indirectly inhibits R5 HIV-1 infection by inducing higher levels of natural CCR5
ligands.
Background
CXCR4 and CCR5 belonging to the family of G-protein
coupled receptors (GPCR) serve as receptors for the
CXC-chemokine stromal derived factor 1 (SDF-1) and
the CC-chemokines MIP-1a,M I P - 1 b and RANTES,
respectively. The ligation of these chemokine receptors
transmits a number of intracellular signals, and the
receptors also serve as co-receptors for HIV-1 [1-5].
Under normal physiological conditions, CXCR4
molecules form closely linked dimers [6] and heterodi-
mers with other chemokine receptors including CCR5
[7]. CXCR4 is expressed extracellularly, consisting of an
N-terminal (NT) region and extracellular loops (ECL) 1,
ECL2 and ECL3. Several lines of evidence indicate that
the interaction between CXCR4 and SDF-1 or HIV-1
involves multiple domains of the receptor. For example,
while the NT and the ECL2 domains appear to be criti-
cal for SDF-1 binding and signaling, the regions contig-
uous to the ECL2 and ECL3 have been implicated in
HIV-1 co-receptor activity and homologous cell adhe-
sion [8-11]. Studies with CXCR4 mutants have revealed
that the HIV-1 co-receptor activity of CXCR4 is
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receptor and/or transduce intracellular signaling [11,12].
Current and prospective anti-HIV-1 therapy includes
the use of small chemical compounds which target che-
mokine receptors that are termed viral occupancy inhi-
bitors (VIROC) [13]. In addition, mAbs against
chemokine receptors have also been shown to have a
potential for HIV-1 inhibition. For example, an anti-
human CCR2 mAb that is neither an agonist nor an
antagonist blocks both X4 and R5 HIV-1, due to oligo-
merization of CCR2 with CCR5 and CXCR4, but not
receptor down-modulation [14]. In addition, an unique
mAb with specificity for the N-terminus region of CCR5
that does not block the interaction between HIV-1
gp120 and CCR5, blocks R5 HIV-1 infection by indu-
cing CCR5 dimerization [15].
Herein, we examined a series of three rat IgG anti-
human CXCR4 mAbs made by our laboratory [16], and
we demonstrate that clone A120, that recognizes a con-
formational epitope encompassing the ECL1 and ECL2
domains of CXCR4, has a unique functional property.
Thus, the interaction of the A120 mAb with CXCR4
inhibits not only X4, but also R5 HIV-1 infection of in
vitro activated PBMCs, via mechanisms detailed herein.
The novel anti-CXCR4 mAb function described in this
study potentially provides a unique adjunct to conven-
tional anti-HIV-1 chemotherapy with activity against
not only CXCR4 but also CCR5 and dual tropic HIV-1.
Results
Suppressive effects of anti-CXCR4 mAbs on HIV-1
infection in primary activated PBMCs
We first tested our 3 different anti-CXCR4 mAb clones
(A145, A120 and A80) for their potential to inhibit the
infection of the prototype X4 HIV-1NL4-3 and for pur-
poses of controlling the prototype R5 HIV-1JR-FL in in
vitro activated primary PBMC cultures. None of these
anti-human CXCR4 mAbs cross-reacts with human
CCR5, and only the A120 mAb can block the SDF-1-
mediated Ca
2+ influx [16]. Thus, the PBMCs infected
with low levels of HIV-1 (at a multiplicity of infection of
lower than 0.01) were cultured for 5 days in the pre-
sence or absence of 10 μg/ml of either anti-CXCR4
mAb or isotype control. As shown in Figure 1a, while
the A145 mAb had minimal inhibitory effect, the A120
and A80 mAbs markedly inhibited the infection of the
Figure 1 Inhibition of HIV-1 infection in activated PBMCs by anti-CXCR4 mAbs. (a) PBMCs activated with anti-CD3/CD28 for 1 day were
infected with either R5 HIV-1JR-FL or X4 HIV-1NL4-3 for 2 hours, washed and then cultured in the presence of 10 μg/ml of the A145, A120, A80 rat
IgG mAbs or isotype control rat IgG mAb mixture. After 5 days, virus production in the culture supernatants was determined by p24 ELISA. (b)
Activated PBMCs infected with R5 HIV-1JR-FL, R5 HIV-1JR-CSF, X4 HIV-1NL4-3 or X4 HIV-1IIIB were aliquoted and cultured in the presence of 10 μg/ml
of the A120 mAb or isotype control mAb. The p24 levels in the culture supernatants were monitored daily by ELISA. Data shown for both (a)
and (b) are representative of 3 independent experiments using PBMCs from different donors.
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t h ei n h i b i t o r yp o t e n t i a lo ft h eA 1 2 0m A bw a st h eh i g h -
est among these mAbs, we selected the A120 mAb for
further characterization. Although the production of
HIV-1 from activated PBMCs was influenced by culture
conditions, mostly cell concentration at time of infection
and cultivation steps, as shown in Figure 1b, the inhibi-
tory effect of A120 mAb was further confirmed using an
additional R5 (JR-CSF) and X4 (IIIB) HIV-1 strains.
To examine tPBMC donor variabilities, the ability of
the A120 mAb to inhibit R5 HIV-1JR-FL and X4 HIV-
1NL4-3 in activated PBMCs from 6 different unrelated
donors was also studied. Viral production was
quantitated by measuring both the levels of p24 and the
frequency of infected cells using flow cytometry as out-
lined in the methods section. As seen in Figure 2a,
whereas there was indeed considerable variability in the
relative susceptibility of in vitro activated PBMCs from
different donors to support R5 and X4 HIV-1 infection,
the addition of the A120 mAb to the cultures showed
variable levels of moderate to significant inhibition in
each case (differences in the ability of PBMCs from dif-
ferent donors to support R5 versus X4 HIV-1 is an
interesting subject that is currently under study). In
addition, the fact that the addition of the A120 mAb
also inhibited the increase in the frequency of infected
Figure 2 The A120 mAb-mediated inhibition of HIV-1 infection in activated PBMCs from different donors. Activated PBMCs from 6
different donors were infected with either R5 HIV-1JR-FL or X4 HIV-1NL4-3 for 2 hours. After extensive washing, the PBMCs were aliquoted and
cultured in the presence of A120 or isotype control IgG at 10 μg/ml. (a) After 3~5 days, virus production was determined by p24 ELISA in the
culture supernatants, and values obtained on day 4 are shown as representative. P values were 0.007 and 0.032 for R5 HIV-1 and X4 HIV-1,
respectively. (b) The PBMC samples obtained on day 4 after infection were fixed and permeabilized, and then stained with anti-HIV-1 p24 mAb
labeled with Alexa Fluor 488 and examined by flow cytometry. The frequencies (percentages) of p24
+ cells were plotted. P values were 0.026
and 0.031 for R5 HIV-1 and X4 HIV-1, respectively. Representative data from 3 independent experiments are shown.
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gests that the A120 mAb inhibits new infection in the
cultures. To our knowledge, this is the first report of an
anti-CXCR4 mAb that inhibits infection of both X4 and
R5 HIV-1 strains in activated PBMCs.
Dose response studies were conducted next to deter-
mine whether differences exist in the inhibition of R5 as
compared with X4 HIV-1. As seen in Figure 3, maxi-
mum inhibition was achieved at a concentration of
more than 5 μg/ml and 0.6 μg/ml for R5 and X4 HIV-1,
respectively. The difference noted in the titration curves
indicates that the potential mechanisms for A120 mAb-
mediated R5 and X4 HIV-1 suppression are likely to be
distinct from each other. The inhibition of virus replica-
tion by the addition of the A120 mAb in these cultures
was not secondary to the presence of non-specific inhi-
bitors in the A120 mAb preparation since the addition
of the same A120 mAb preparation to the CXCR4
expressing HIV-1 producing Molt-4/IIIB cell line and
the HTLV-1 producing MT-2 cell line had no detectable
effect on virus production (Figure 4). Because the two
cell lines express high levels of CXCR4 that readily
binds the A120 mAb, it appears that the mere ligation
of CXCR4 via A120 mAb epitope does not interfere
with the virus production from these cell lines.
One of the trivial explanations for the R5 HIV-1 sup-
pression by the anti-CXCR4 mAb could be ascribed to
the potential presence of LPS in the A120 mAb prepara-
tion. However, it is highly unlikely, because (1) the A120
mAb preparation contained little LPS since it was
repeatedly passed through a polymyxin B column to
eliminate possible LPS contamination, (2) exogenously
added LPS at 0.1 μg/ml did not inhibit R5 HIV-1 infec-
tion in the same culture conditions, and (3) the inclu-
sion of anti-human CD14 mAb that blocks the binding
of LPS failed to interfere with the A120 mAb-mediated
R5 HIV-1 inhibition (Figure 5). As seen in Figure 5a,
while the addition of the A120 mAb clearly inhibited
the generation of syncytia by R5 HIV-1JR-FL and p24
production, there was no detectable inhibition with the
addition of LPS. The facts that LPS at 0.1 μg/ml failed
to inhibit HIV-1 production (unlike the A120 mAb) and
that the addition of anti-CD14 mAb (which blocks LPS
binding to its receptor, CD14) did not reverse the inhi-
bition of R5 HIV-1 infection suggest that the activity of
the A120 mAb is not due to LPS contamination.
Altogether, these data document that the anti-human
CXCR4 mAb, clone A120, which ligates CXCR4 mole-
cules via the ECL1/ECL2 domains potently inhibited not
only X4 but also R5 HIV-1 strains in freshly in vitro
activated primary PBMC cultures.
Enhancement of the production of the CCR5 binding b-
chemokines and reduction of CCR5 expression by A120
mAb treatment
The present observations that the anti-CXCR4 A120
mAb inhibited the production of R5 HIV-1 in activated
PBMCs prompted us to examine whether CCR5 binding
b-chemokines were involved. Thus, we tested whether
neutralizing mAbs against human MIP-1a,M I P - 1 b and
RANTES could reverse the effects of the A120 mAb on
v i r u si n f e c t i o n .A ss h o w ni nF i g u r e6 ,i n d e e dt h eA 1 2 0
mAb-mediated inhibition of R5 HIV-1 infection was sig-
nificantly reversed by anti-MIP-1a mAb and partially by
anti-MIP-1b but not anti-RANTES mAb. These data
suggest that MIP-1a and possibly MIP-1b were likely
the major factors involved in the inhibition of R5 HIV-1
infection. As expected, the addition of these anti-b-che-
mokine mAbs did not reverse A120 mAb-mediated
blocking of X4 HIV-1 infection (data not shown). How-
ever, this b-chemokine dependent mechanism for the
inhibition of R5 HIV-1 by the addition of the A120
mAb is donor-dependent. Notably, the addition of the
anti-chemokine mAbs failed to reverse the A120 mAb
mediated inhibition of R5 HIV-1 in cultures of PBMCs
from 2 of the 6 donors. The reason(s) for this resistance
in these donors remains to be studied.
T oc o n f i r mt h a tt h eb-chemokines were indeed pro-
duced by the ligation of CXCR4 by the A120 mAb in
activated PBMCs, we quantitated the concentration of
these chemokines. Figure 7a shows that the A120 mAb
enhanced the synthesis of MIP-1a and MIP-1b in most
if not all the cases. Although enhanced RANTES pro-
duction was seen in 3 out of the 6 donors, it is unlikely
Figure 3 Dose responses of the A120 mAb-mediated inhibition
of R5 and X4 HIV-1 infection in activated PBMCs. Activated
PBMCs from the donors were infected with either R5 HIV-1JR-FL or
X4 HIV-1NL4-3. After washing, the PBMCs were aliquoted and
cultured in the presence of graded concentrations of the A120 mAb
for 4 days. Virus production in the culture supernatant was
determined by p24 ELISA. Representative data from 3 independent
experiments using 3 different donors’ PBMCs are shown.
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HIV-1 inhibition as shown in Figure 6. As expected,
treatment of activated PBMCs with the A120 mAb led
to a significant reduction in the frequency of cells
expressing CCR5 (Figure 7b and 7c). In contrast, there
appeared to be a slight increase in the frequency of
CXCR4 expressing CD4
+ T cells (Figure 7b and 7c).
Therefore, these results indicate that the incubation of
Figure 4 The A120 mAb does not affect HIV-1 and HTLV-I production from producer cell lines. The X4 HIV-1IIIB producer cell line (Molt-4/
IIIB) and the HTLV-I producer cell line (MT-2) cells were cultured in the presence of 10 μg/ml of A120 or control mAb for 3 days. The culture
supernatants were assayed for HIV-1 p24 and HTLV-I p24 by standard ELISA.
Figure 5 LPS is not involved in the A120 mAb-mediated inhibition of HIV-1 infection. Activated PBMCs infected with R5 HIV-1JR-FL were
cultured in the presence or absence of LPS (0.1 μg/ml) or the A120 mAb with or without anti-CD14 mAb. After 4 days, syncytium formation and
virus production in the culture supernatants were determined microscopically (a) and using a p24 ELISA kit (b), respectively.
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inhibited R5 HIV-1 infection primarily via the blockade
of the co-receptor function of CCR5, most likely due to
its ability to induce the synthesis of CCR5-binding b-
chemokines. It is important to note that the levels of
MIP-1a induced by the A120 mAb showed a typical
dose response curve (Additional file 1), and the level of
R5 HIV-1 inhibition was inversely-correlated with levels
of MIP-1a detected.
Cell populations that produce the b-chemoknes
In an effort to identify the cell lineage that was involved
in the synthesis of the b-chemokines following incuba-
tion of the activated PBMCs in the presence of the
Figure 6 Reversal of the A120 mAb-mediated inhibition of R5 HIV-1 infection in activated PBMCs with anti-CCR5 ligand-neutralizing
mAbs. Activated PBMCs from 6 donors were infected with R5 HIV-1JR-FL and cultured in the presence of 10 μg/ml A120 mAb or isotype control
mAb together or without anti-chemokine mAbs including anti-MIP-1a, anti-MIP-1b or anti-RANTES at 10 μg/ml for 4 days. Virus production in
the culture supernatants was determined by p24 ELISA. The p24 levels were plotted as percent of control values obtained in cultures incubated
in each anti-b-chemokine mAb for each donor.
Figure 7 The A120 mAb-treatment induces the production of CCR5 binding b-chemokines and the down-modulation of CCR5
expression. PBMCs from 6 donors were activated with anti-CD3/28 mAbs for 1 day, washed, aliquoted and then incubated in the presence of
10 μg/ml A120 mAb or isotype control mAb for an additional day. (a) Changes in the concentrations of MIP-1a, MIP-1b and RANTES in the
culture supernatants were assayed by ELISA. (b and c) Cells were analyzed for changes in the cell surface expression of CCR5 and CXCR4 on
gated populations of CD4
+T cells (MFI denotes mean fluorescence intensity). A representative flow cytometry dot blot profile is shown.
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Thus, aliquots of activated PBMCs were depleted of
CD19
+ Bc e l l s ,C D 4
+ T cells, CD8
+ Tc e l l so rC D 1 4
+
monocytes utilizing immune-beads conjugated with the
appropriate lineage specific mAbs. Non-depleted (mock)
and each cell lineage depleted PBMCs were cultured for
24 hours in the presence or absence of 10 μg/ml of
A120 mAb. As shown in Figure 8, the most marked
reduction in b-chemokine levels in the culture superna-
tants was noted in cultures depleted of CD14
+ mono-
cytes followed by those depleted of CD4
+ T cells and
CD8
+ T cells. However, B-cell depletion had minimal if
any effect on the levels of b-chemokines synthesized.
These results suggest that activated T cells along with
monocytes were responding to the A120 mAb by secret-
ing b-chemokines.
A120 mAb exhibits broad HIV-1 clade inhibition
Finally, the unique availability of a panel of HIV-1 with
distinct co-receptor usage and clades prompted us to
examine the breadth of inhibitory activity of the A120
mAb. Once again, aliquots of 1-day anti-CD3/28 acti-
vated PBMCs were infected with 15 different HIV-1
strains and then cultured in the presence of 10 μg/ml of
the A120 mAb or control IgG, and the levels of p24 in
the supernatant fluids were quantitated on day 5 after
infection. As shown in Table 1, incubation of the cul-
tures in the presence of the A120 mAb uniformly led to
a marked decrease in the levels of p24 for all ten R5
HIV-1 strains, three X4 HIV-1 strains, and two dual R5/
X4 tropic HIV-1 strains (p = 0.0065).
Discussion
The present study is the first report that documents
t h eu n i q u ep r o p e r t yo fa na n t i - h u m a n C X C R 4m A b
(clone A120) which upon ligation of CXCR4 via the
ECL1/ECL2 domains strongly blocks the infection of
not only X4 but also R5 and dual tropic HIV-1 strains
in freshly in vitro activated PBMC cultures. The
mechanism for the inhibition of the X4 HIV-1 is likely
due to direct interference and binding of gp120 to
CXCR4 as reported previously. In addition, since A120
mAb treatment increases CXCR4 expression on CD4
+
T cells (Figure 7), it may also be possible that the
A120 mAb may block X4 HIV-1 infection by interfer-
ing with CXCR4 trafficking. By contrast, the predomi-
nant mechanism for the inhibition of the R5 HIV-1
infection by the A120 mAb is most likely due to the
production of the CCR5-binding b-chemokines, espe-
cially MIP-1a, from activated T cells and monocytes
leading to down-modulation of CCR5 expression on
CD4
+ T cells. The observations that the anti-CXCR4
N-terminus mAb (clone A145) showed little or no
inhibition, and the anti-CXCR4 ECL3 mAb (clone
A80) was not as potent in inhibiting HIV-1 infection,
as compared with the A120 mAb, indicate that the
ligation via the ECL1 and/or ECL2 domains is critical
for the inhibition of R5 and X4 HIV-1 infection. This
view is supported by the finding that a panel of com-
mercially available murine mAbs, whose reactive sites
were localized to the ECL1/ECL2 domains or the sin-
gle ECL2 domain of CXCR4, also showed similar, but
less effective suppressive effects on infection with both
the X4 and R5 HIV-1 and enhanced MIP-1a and b
production under the same culture conditions pre-
sented herein (data not shown).
Preliminary data indicate that chemically inactivated
X4 HIV-1 (HIV-1IIIB) and recombinant SDF-1 did not
induce the synthesis of such b-chemokines or inhibit R5
HIV-1 infection in activated PBMCs (data not shown).
Thus, it is important to point out that ligation of
CXCR4 by its natural ligand SDF-1 or HIV-1 gp120 is
not sufficient for generating signals suitable for the
synthesis of the CCR5 ligands, and that ligation of
CXCR4 via specific domains is required for these unique
anti-HIV-1 activities.
Figure 8 The A120 mAb stimulates T cells and monocytes to produce b-chemokines in activated PBMCs. One day-activated PBMCs were
depleted of CD19
+B cells, CD4
+T cells, CD8
+T cells and/or CD14
+monocytes using immunobeads conjugated with appropriate lineage specific
mAbs, and then cultured in the presence of A120 mAb or isotype control mAb for one day. Concentrations of MIP-1a, MIP-1b and RANTES in
the culture supernatants were assayed by ELISA. Representative data from three independent experiments are shown.
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infection has also been reported in a study utilizing
anti-human CCR2 mAb that is neither agonistic nor
antagonistic [14]. It was reasoned that this anti-CCR2
mAb functions by the induction of hetero-oligomeriza-
tion of CCR2 with CCR5 and CXCR4, but not receptor
down-modulation. Another report showed that a non-
agonistic/antagonistic anti-CCR5 N-terminus specific
mAb that is unable to block the binding of R5 HIV-1
g p 1 2 0t oC C R 5i n t e r f e r e sw i t hR 5H I V - 1i n f e c t i o nb y
induction of CCR5 dimerization rather than down-mod-
u l a t i o no fC C R 5[ 1 6 ] .I ti so fi n t e r e s tt on o t et h a tt h i s
anti-CCR5 mAb does not inhibit X4 HIV-1. Thus, our
finding that ligation of CXCR4 via the ECL1/ECL2
region on activated PBMCs results in the production of
CCR5-binding b-chemokines followed by down-modula-
tion of CCR5 expression is unique. However, it remains
to be determined whether the ligation of CXCR4 with
the A120 mAb similarly induces hetero-dimerization of
CXCR4 with CCR5 or the other chemokine receptors or
CCR5 homo-dimerization. Further studies are in pro-
gress using immunoprecipitation and Western blot tech-
niques utilizing appropriate mAbs.
It is important to note that the addition of anti-che-
mokine mAbs did not show the same degree of reversal
of the A120 mAb-induced inhibition of R5 HIV-1 infec-
tion in the cultures from 2 out of the 6 PBMC donors
(Figure 6). In addition, there was a lack of correlation
between enhanced b-chemokine levels and the reversing
effects of the anti-b-chemokine antibodies on the A120-
mediated R5 HIV-1 inhibition. We assume that the con-
centration of the b-chemokine antibodies (10 μg/ml)
was sufficient to neutralize endogenously produced b-
chemokines as the antibodies at this concentration
could neutralize > 100 ng/ml of each of the recombinant
b-chemokines (data not shown). While resistance of
these donors was not due to the production of some
other anti-HIV-1 factor such as CD8
+T lymphocyte
antiviral factor (CAF) [17], it may be possible that treat-
ment with the A120 mAb might induce the hetero-
dimerization of CXCR4 and CCR5 which results in
resistance to R5 HIV-1 infection. Further studies are in
progress to address this issue. It is interesting to note
that among the neutralizing mAbs against the b-chemo-
kines, the anti-MIP-1a mAb was the most effective in
reversing the A120 mAb-induced R5 HIV-1 inhibition.
Since all the available anti-MIP-1a mAbs at present do
not distinguish MIP-1a (LD78a) from its homologue
CCR3L1 product (LD78b) [18], it is possible that
CCR3L1 protein is also produced upon A120 mAb
treatment and involved in the R5 HIV-1 inhibition. As
CCR3L1 is known to be a potent factor that may delay
the progression to clinical AIDS [19], it will be impor-
tant to determine whether A120 mAb stimulates the
production of CCR3L1 proteins. Such studies are also in
progress.
Table 1 Suppressive effect of the A120 mAb on various clades of HIV-1 strains.
Member HIV-1 Subtype Isolate Country of Origin Syncytium Co-receptor Usage Percent inhibition of p24 production
PRD320-01 A UG275 Uganda NSI CCR5 88.3%
PRD320-02 A I-2496 Ghana NSI CCR5 99.8%
PRD320-03 CRF02_AG DJ263 Djibouti NSI CCR5 94.7%
PRD320-04 CRF02_AG POC44951 Liberia NSI CCR5 99.7%
PRD320-06 B BZ167 Brazil SI CXCR4 97.2%
PRD3200-7 C DJ259 Djibouti NSI CCR5 91.5%
PRD320-08 C ZAM18 Zambia NSI CCR5 93.7%
PRD320-09 D SE365 Senegal SI CXCR4 98.5%
PRD320-10 D UG270 Uganda SI CXCR4 99.7%
PRD320-11 CRF01_AE ID17 Indonesia NSI CCR5 81.0%
PRD320-12 CRF01_AE NP03 Thailand SI CXCR4 94.5%
PRD320-14 F BCI-R07 Romania SI CXCR4/CCR5 99.4%
PRD320-15 G BCF-DIOUM Zaire NSI CCR5 99.9%
PRD320-16 G HH8793 Kenya NSI CCR5 83.3%
PRD320-17 H BCF-KITA Zaire NSI CCR5 92.5%
PRD320-18 O BCF06 Cameroon SI CXCR4/CCR5 98.3%
PRD320-19 O I-2478B US NSI CCR5 65.6%
Anti-CD3/CD28 activated PBMCs were infected with each of 15 different HIV-1 strains belonging to various clades and with previously defined different CXCR4
and CCR5 usages. HIV-1 dose of 10 ng p24 value was added to 1 × 10
6 cells for infection. After washing, PBMCs were aliquoted and cultured in triplicate in the
presence of 10 μg/ml of the A120 mAb or isotype control IgG for 5 days. Virus production was determined by quantitation of p24 in the culture supernatants by
ELISA and the mean values calculated. Percent inhibition was calculated relative to the values obtained with the isotype control mAb alone. Representative data
from three independent experiments are shown.
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ving either the selection of pre-existing CXCR4 tropic
HIV-1 and/or due to the evolution of Env variants has
been well documented [20]. Thus, in such cases, the
availability of a reagent like the A120 mAb that has
inhibitory properties for both CCR5 and CXCR4 tropic
HIV-1 may provide a unique therapeutic tool worthy of
consideration. Since the A120 mAb also inhibits the
SIV-1 infection in activated PBMCs from rhesus maca-
ques (Takahashi et al., unpublished), this hypothesis is
currently being investigated using the nonhuman pri-
mate model.
Conclusions
Data described herein have identified a unique epitope
o fC X C R 4w h o s el i g a t i o nn o to n l yd i r e c t l yi n h i b i t s
CXCR4 tropic HIV-1, but also indirectly inhibits the
infection of R5 tropic HIV-1 via the synthesis of natural
CCR5 ligands.
Methods
Reagents
RPMI 1640 medium (Sigma-Aldrich. Inc. St. Louis, MO)
supplemented with 10% fetal calf serum (FCS), 100 U/
ml of penicillin and 100 μg/ml of streptomycin (herein-
after called RPMI medium) was utilized for the
described studies. Anti-human CD3 (clone OKT-3) and
anti-CD28 (clone 28.2) were obtained from the Ameri-
can Type Culture Collection (Rockville, MD) and BioLe-
gend (San Diego, CA), respectively. Neutralizing mAbs
against human RANTES, MIP-1a and MIP-1b were
purchased from R&D systems (Minneapolis, MN). The
r a ta n t i - C X C R 4m A b su s e dw e r ep r o d u c e di no u r
laboratory and included clones A145 (IgG1), A120
(IgG2b) and A80 (IgG1) [16]. Mapping of the epitopes
recognized by these mAbs was reported previously [16].
Other rat mAbs used were IgG1 anti-CCR5, IgG2b anti-
HTLV-I gp46 and IgG1 anti-HCV produced in our
laboratory [16,21,22]. These mAbs were purified from
CB.17-SCID mouse ascites fluids by ammonium sulfate
precipitation followed by gel filtration using Superdex
G-200 (GE), and passed through a polymyxin B column
to remove potential LPS contamination. The fluorescent
dye-labeled anti-human CD4, CD8, CD14 and CD19
mAbs were purchased from Beckman-Coulter or BioLe-
gend. The anti-HIV-1 p24 mAbs used were also pro-
duced in our laboratory. Magnetic beads conjugated
with mAbs against human CD4, CD8, CD14 or CD19
w e r ep u r c h a s e df r o mD y n a la n du s e da c c o r d i n gt ot h e
manufacturer’s recommendation. Low endotoxin murine
anti-CXCR4 mAbs including clone 12G5 and the other
anti-CXCR4 ECL2 mAbs were purchased from BioLe-
gend and R&D.
HIV-1 preparation
V i r u ss t o c k so fR 5H I V - 1 JR-FL,R 5H I V - 1 JR-CSF and X4
HIV-1NL4-3 were produced by transfection of the 293T
cells with the appropriate HIV-1 infectious plasmid
DNAs utilizing the calcium phosphate method as
described previously [23]. X4 HIV-1IIIB was produced in
the Molt-4/IIIB cell line. The other HIV-1 isolates used
were from the HIV subtype infectivity panel PRD320
(BBI Diagnostics, West Bridgewater, MA, USA) which
included clade A R5 HIV-1 (UG275, I-2496 isolates),
clade CRF02AG R5 HIV-1 (DJ263, POC44951 isolates),
clade B R5 (US2 isolate) and X4 HIV-1 (BZ167 isolate),
clade C R5 HIV-1 (DJ259, ZAM18 isolates), clade D X4
HIV-1 (SE365, UG270 isolates), clade CRF01AE R5
(ID17 isolate) and X4 HIV-1 (NP03 isolate), clade F R5
(BZ163 isolate) and X4/R5 HIV-1 (BCI-R17 isolate),
clade G R5 HIV-1 (BCF-DIOUM, HH8793 isolates),
clade H R5 HIV-1 (BCF-KITA isolate), clade O R5 (I-
2478B isolate) and X4/R5 HIV-1(BCF06 isolate). Each of
these panel HIV-1 strains was grown in primary PHA-
activated PBMCs and the levels of p24 determined and
10 ng of p24 used to infect PBMCs. These HIV-1 stocks
were aliquoted and stored at -80°C until used.
In vitro stimulation of PBMCs and infection with HIV-1
PBMCs from healthy donors were obtained by density
gradient centrifugation on HistoPAQUE-1077 (Sigma-
Aldrich), suspended at 2 × 10
6 cells/ml in RPMI med-
ium, dispensed into individual wells of 24-well plates
(BD) (1 ml/well) pre-coated with 5 μg/ml anti-CD3
mAb (OKT-3) and cultured in the presence of soluble
0.1 μg/ml anti-CD28 mAb at 37°C in a 5% CO2 humi-
dified atmosphere for 24 hours. The activated PBMCs
were collected, washed once and infected with HIV-1
at a multiplicity of infection (m.o.i.) of 0.005~0.01 or
at 10 ng p24 per 1~2 × 10
6 cells for 2 hours. Infected
PBMCs were washed three times, re-suspended at
0.5~1 × 10
6 cells/ml in RPMI medium containing 20
U/ml recombinant human IL-2 containing RPMI med-
ium, dispensed into individual wells of 48-well plates
(BD) (0.5 ml/well) and then cultured in the presence
or absence of various concentrations of the anti-
CXCR4 or control mAbs. Production of HIV-1 was
determined by the measurement of HIV-1 core p24
levels by ELISA, and the number of HIV-1 p24
+ cells
were determined by FCM as described previously [24].
For select experiments, activated PBMCs were cultured
at 1 × 10
6 cells/ml in RPMI medium containing 20 U/
ml IL-2 in the presence or absence of 10 μg/ml of
A120 mAb for 24 hours, and the culture supernatants
were collected, and the levels of b-chemokines were
determined by ELISA. All the experiments in this
study were performed in triplicate wells.
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Molt-4/IIIB [25] and MT-2 [26] cells that were produc-
tively infected with HIV-1IIIB (Molt-4/IIIB) and human
T cell leukemia virus type-I (HTLV-I), respectively, were
cultured in RPMI medium. HIV-1 and HTLV-I produc-
tion were determined by our in-house HIV-1 p24 and
HTLV-I p24 sandwich ELISA kits (Tanaka et al.,
unpublished).
Flow Cytometry (FCM)
Cells to be analyzed were Fc-blocked with 2 mg/ml nor-
mal human pooled IgG on ice for 15 minutes, and ali-
quots of these cells were subjected to staining using
pre-determined optimum concentrations of fluorescent
dye-conjugated mAbs for 30 minutes on ice. The cells
were then washed using FACS buffer (PBS containing
2% FCS and 0.1% sodium azide), fixed in 1% paraformal-
dehyde (PFA) in FACS buffer and analyzed using a
FACS Calibur. The data obtained were analyzed using
the Cell Quest software (BD). For detection of HIV-1
infected cells, cells were fixed with 4% PFA-containing
PBS for 5 min at room temperature followed by washing
with 0.1% Saponin-containing FACS buffer. These cells
were then Fc-blocked with 2 mg/ml normal human
pooled IgG on ice for 15 min, and aliquots of these cells
were stained with Alexa Fluor 488-conjugated anti-HIV-
1 p24 mAb (clone 2C2) for 30 min on ice. The cells
were then washed using FACS buffer and the frequency
and the absolute number of p24+ cells determined by
FCM using a cell counting kit (BD) according to the
manufacturer’s protocol.
Statistical analysis
Data were tested for significance using the Student’s t
test using the Prism software (GraphPad Software).
Additional material
Additional file 1: Dose response of the A120 mAb-mediated MIP-1a
production in activated PBMCs. As described in the legend for Figure
7, activated PBMCs were incubated in the presence of graded
concentrations of the A120 mAb or isotype control mAb for an
additional day. Changes in the concentrations of MIP-1a in the culture
supernatants were assayed by ELISA. Isotype control mAbs did not
enhance MIP-1a production at 0.5~20 μg/ml in these culture conditions
(data not shown). Representative data are from 3 independent
experiments using PBMCs from a single donor.
Lists of abbreviations used
HIV: human immunodeficiency virus; PBMC: peripheral blood mononuclear
cells; mAb: monoclonal antibody; X4: CXCR4-tropic; R5: CCR5-tropic; ECL:
extra-cellular loop.
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